- Report
- August 2024
- 127 Pages
North America
From €3039EUR$3,450USD£2,671GBP
- Report
- June 2024
- 80 Pages
Middle East, Africa
From €3039EUR$3,450USD£2,671GBP
- Report
- June 2024
- 76 Pages
North America
From €3039EUR$3,450USD£2,671GBP
- Report
- September 2024
- 150 Pages
Global
From €3391EUR$3,850USD£2,981GBP
€4272EUR$4,850USD£3,755GBP
- Report
- October 2023
Global
From €3171EUR$3,600USD£2,787GBP
- Report
- October 2023
North America
From €1321EUR$1,500USD£1,161GBP
- Report
- November 2022
- 408 Pages
Global
From €3171EUR$3,600USD£2,787GBP
- Report
- October 2025
- 92 Pages
Qatar
From €4272EUR$4,850USD£3,755GBP
Continuous bioprocessing is a biotechnology-based approach to the production of biopharmaceuticals, such as vaccines, monoclonal antibodies, and recombinant proteins. It involves the use of continuous manufacturing techniques, such as continuous cell culture, continuous chromatography, and continuous purification, to produce biopharmaceuticals in a more efficient and cost-effective manner than traditional batch-based processes. This approach also allows for greater control over the production process, resulting in higher quality products.
Continuous bioprocessing has become increasingly popular in recent years, as it offers a number of advantages over traditional batch-based processes. These include improved process control, increased product yield, reduced production costs, and shorter production times.
Some companies in the continuous bioprocessing market include Merck KGaA, Novartis, Pfizer, Sanofi, and Lonza. Show Less Read more